Literature DB >> 15834293

Comparative effects of the angiotensin II receptor blocker, telmisartan, and the angiotensin-converting enzyme inhibitor, ramipril, on cerebrovascular structure in spontaneously hypertensive rats.

François Dupuis1, Jeffrey Atkinson, Patrick Limiñana, Jean-Marc Chillon.   

Abstract

OBJECTIVE: Antihypertensive treatment with angiotensin-converting enzyme inhibitors (ACEIs) reverses cerebral arteriolar remodeling, thus restoring dilatation and hence the lower limit of cerebral blood flow (CBF) autoregulation (LLCBF). The objective of this study was to determine whether angiotensin II receptor AT1 blockers (ARBs) produce the same effect.
DESIGN: We examined the effects of treatment with an ARB [telmisartan (TEL), 1.93 +/- 0.04 mg/kg per day] or an ACEI [ramipril (RAM), 1.00 +/- 0.02 mg/kg per day] on the cerebral circulation in spontaneously hypertensive rats (SHR).
METHODS: Arteriolar pressure and diameter (cranial window) and CBF (laser Doppler) were measured during stepwise hypotensive hemorrhage, before and after deactivation (ethylenediamine tetraacetic acid), in untreated Wistar-Kyoto (WKY) rats and SHR untreated or treated for 3 months with TEL or RAM in the drinking water.
RESULTS: Treatment normalized arteriolar internal diameter (SHR, 38 +/- 3 microm; TEL, 52 +/- 2 microm; RAM, 50 +/- 2 microm; WKY, 58 +/- 4 microm), essentially by reversing eutrophic inward remodeling, and the LLCBF (SHR, 80 +/- 11 mmHg; TEL, 60 +/- 4 mmHg; RAM, 71 +/- 6 mmHg; WKY, 57 +/- 5 mmHg).
CONCLUSION: The fact that the ARB (TEL) is as effective as an ACEI (RAM) in reversing cerebral arteriolar remodeling suggests that the cerebrovascular AT1 receptor is an underlying mechanism that promotes hypertensive eutrophic inward remodeling.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15834293     DOI: 10.1097/01.hjh.0000166848.95592.a5

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  18 in total

1.  Double blockade of angiotensin II (AT(1) )-receptors and ACE does not improve weight gain and glucose homeostasis better than single-drug treatments in obese rats.

Authors:  Anja Miesel; Helge Müller-Fielitz; Olaf Jöhren; Florian M Vogt; Walter Raasch
Journal:  Br J Pharmacol       Date:  2012-04       Impact factor: 8.739

2.  Magnetic resonance imaging quantification of regional cerebral blood flow and cerebrovascular reactivity to carbon dioxide in normotensive and hypertensive rats.

Authors:  Renata F Leoni; Fernando F Paiva; Erica C Henning; George C Nascimento; Alberto Tannús; Draulio B de Araujo; Afonso C Silva
Journal:  Neuroimage       Date:  2011-06-25       Impact factor: 6.556

3.  PPAR{gamma} activation prevents hypertensive remodeling of cerebral arteries and improves vascular function in female rats.

Authors:  Marilyn J Cipolla; Nicole Bishop; R Saman Vinke; Julie A Godfrey
Journal:  Stroke       Date:  2010-04-15       Impact factor: 7.914

4.  Compromised regulation of tissue perfusion and arteriogenesis limit, in an AT1R-independent fashion, recovery of ischemic tissue in Cx40(-/-) mice.

Authors:  Jennifer S Fang; Stoyan N Angelov; Alexander M Simon; Janis M Burt
Journal:  Am J Physiol Heart Circ Physiol       Date:  2013-01-04       Impact factor: 4.733

5.  Effects of spironolactone on cerebral vessel structure in rats with sustained hypertension.

Authors:  Christiné S Rigsby; Adviye Ergul; Vera Portik Dobos; David M Pollock; Anne M Dorrance
Journal:  Am J Hypertens       Date:  2011-02-24       Impact factor: 2.689

6.  S-nitrosoglutathione inhibits cerebrovascular angiotensin II-dependent and -independent AT1 receptor responses: A possible role of S-nitrosation.

Authors:  Marie-Lynda Bouressam; Sandra Lecat; Alexandre Raoul; Caroline Gaucher; Caroline Perrin-Sarrado; Isabelle Lartaud; François Dupuis
Journal:  Br J Pharmacol       Date:  2019-05-07       Impact factor: 8.739

Review 7.  The effects of hypertension on the cerebral circulation.

Authors:  Paulo W Pires; Carla M Dams Ramos; Nusrat Matin; Anne M Dorrance
Journal:  Am J Physiol Heart Circ Physiol       Date:  2013-04-12       Impact factor: 4.733

Review 8.  New standards in hypertension and cardiovascular risk management: focus on telmisartan.

Authors:  Domenico Galzerano; Cristina Capogrosso; Sara Di Michele; Antonio Galzerano; Paola Paparello; Diana Lama; Carlo Gaudio
Journal:  Vasc Health Risk Manag       Date:  2010-03-24

9.  Cerebrovasculoprotective effects of azilsartan medoxomil in diabetes.

Authors:  Mohammed Abdelsaid; Maha Coucha; Adviye Ergul
Journal:  Transl Res       Date:  2014-06-17       Impact factor: 7.012

Review 10.  Vasotrophic regulation of age-dependent hypoxic cerebrovascular remodeling.

Authors:  Jinjutha Silpanisong; William J Pearce
Journal:  Curr Vasc Pharmacol       Date:  2013-09       Impact factor: 2.719

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.